Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326704 | 1.00 | SPHK1 (0.45) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL6918603 | 1.00 | SPHK1 (0.45) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL30484737 | 0.88 | SPHK1 (0.47) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL13964493 | 0.88 | SPHK1 (0.47) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL8445237 | 0.88 | SPHK1 (0.46) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL14357932 | 0.88 | SPHK1 (0.46) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL14489664 | 0.87 | SPHK1 (0.46) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL2328925 | 0.87 | SPHK1 (0.46) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL1863729 | 0.87 | SPHK1 (0.46) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL1863728 | 0.87 | SPHK1 (0.46) | SPHK1HSD11B2BRD4HCRTR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2074108-B3 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2581366-A1 | Renin Inhibitors | Vitae Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2074108-B1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-6995142-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-6906198-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1073672-B1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1329457-A2 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | DRAGOVICH PETER SCOTT (US) | 2003-07-10 | — | — | US | disclosed |
| US-6531452-B1 | Peptide-like and peptidomimetic compounds that inhibit enzymatic activity of picornaviral 3C proteases and inhibit picornavirus replication | AGOURON PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1073672-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057135-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | SPHK1 798/4885HSD11B2 2068/4885BRD4 1079/4885 |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | SPHK1 3301/4885HSD11B2 1606/4885BRD4 2599/4885 |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | SARNP, RNASE1, SERPINA3 | SPHK1 3420/4885HSD11B2 3250/4885BRD4 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.